

Special Issue

CAR T cell Immunotherapy—the Living Drugs for Lethal Diseases

Message from the Guest Editors

Chimeric Antigen Receptor (CAR) expressed in autologous T cells targeting B lymphocyte antigen CD19 has been successfully scaled to clinical setting for relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and diffuse B cell lymphoma (DBCL).

Tisagenlecleucel (Kymriah) and Axicabtagene ciloleucel (Yescarta) have been the first “living drugs”. However, other CAR expressed on different effector cells targeting tumor specific antigens are being faster developed for other malignancies and catastrophic diseases. In this current perspective, it has revalued the immunotherapy as a hopeful treatment based on specific cell recognition and activation. The aim of this Special Issue is to provide an overview of the CAR cell field biology from the basic and translational development to the manufacturing and clinical impact and future challenges. We hope that the reports presented by basic and clinical researchers will be a valuable for continuous improvement for the community of researchers and physicians investigating on CAR cells in different diseases and aims and objectives.

Guest Editors

Dr. Antonio Pérez Martínez

Department of Pediatrics, University Hospital La Paz, Universidad Autónoma de Madrid, Paseo de la Castellana 261, 28046 Madrid, Spain

Dr. Patrick Schlegel

Abteilung I (Hämatologie/Onkologie), Universitätsklinik für Kinder und Jugendmedizin, Hoppe-Seyler-Straße 1, 72076 Tübingen, Germany

Deadline for manuscript submissions

closed (28 February 2022)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/60052

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).